IVEVF (Inventiva) 10-Year Sortino Ratio: N/A (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IVEVF Inventiva SA IVEVF
34 GF Score
Price $3.59
GF Value $0.24
! 7 Warning Signs
View Full Analysis

What is Inventiva 10-Year Sortino Ratio?

The 10-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past ten years. As of today (2026-09-21), Inventiva's 10-Year Sortino Ratio is Not available.


Inventiva  (OTCPK:IVEVF) 10-Year Sortino Ratio Explanation

The 10-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past ten year. It is calculated as the annualized result of the average ten-year monthly excess returns divided by the standard deviation of negative returns in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.


Inventiva 10-Year Sortino Ratio Related Terms


IVEVF vs VRTX, REGN, MRNA: 10-Year Sortino Ratio Comparison

For the Biotechnology subindustry, Inventiva's 10-Year Sortino Ratio, along with its competitors' market caps and 10-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inventiva 10-Year Sortino Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inventiva's 10-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where Inventiva's 10-Year Sortino Ratio falls into.


IVEVF
34GF Score
Inventiva SA IVEVF
10-Year Sortino Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inventiva 10-Year Sortino Ratio Calculation

The 10-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last ten year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 10-Year Sortino Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past ten year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.

Is Inventiva (IVEVF) Overvalued in 2026?

Based on GuruFocus' analysis, Inventiva stock appears to be overvalued. The current stock price of $3.59 is trading 1395.8% above its estimated GF Value™ of $0.24.

Key valuation signals for IVEVF:

  • 10-Year Sortino Ratio: N/A
  • GF Value™: $0.24 vs. price of $3.59 (1395.8% above fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the IVEVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Inventiva Business Description

Address 50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
34GF Score

Get the complete analysis for IVEVF

10-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.59
Price
$0.24
GF Value